COMP <GO>
ELDN vs EVMN // EV/EBITDA & P/E VALUATION
Eledon Pharmaceuticals Inc. (NASDAQ) VS. Evommune Inc. (NYSE) • 15-METRIC TALLY: ELDN 1
— EVMN 2
■ METRIC PARITY
LAST: $3.04 (+10.15%) • MKT CAP: $247.0M
valuation
—
LAST: $6.81 (+7.92%) • MKT CAP: $247.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELDN VS. EVMN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELDN | EVMN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 85.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.87 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | EVMN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.0 | 49.5 | +8.52 | ELDN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $247.0M | $247.1M | -$115.4K | EVMN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELDN REV | EVMN REV | ELDN GROSS % | EVMN GROSS % | ELDN FCF | EVMN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $13.0M | — | — | -$62.3M | -$76.7M |
| FY 2024 | $0 | $7.0M | — | — | -$47.3M | -$58.3M |
| FY 2023 | $0 | — | — | — | -$39.5M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELDN // BETA —
EVMN // BETA —